- Evonik partners with InVitria to supply animal-free recombinant human serum albumin.
- InVitria's rHSA is produced in a non-mammalian host, reducing contamination risks.
- The recombinant human serum albumin market is projected to grow nearly 10% CAGR from 2025 to 2033.
- Evonik aims to expand its recombinant protein portfolio through this collaboration.
Partnership Overview
Evonik has formed a strategic partnership with InVitria to supply animal component-free recombinant human serum albumin (rHSA) to the global biopharmaceutical industry. This collaboration combines Evonik's expertise in cell culture ingredients with InVitria's advanced recombinant production technology.
Product Benefits
InVitria's rHSA is a highly pure recombinant version of albumin, produced in a non-mammalian host. This method eliminates reliance on animal- or human-derived serum proteins, reducing risks of contamination, supply limitations, and batch variability. The result is a safer, more consistent ingredient that enhances process efficiency and product stability across various biopharmaceutical applications.
Market Growth
The market for recombinant human serum albumin is projected to grow nearly 10 percent CAGR from 2025 to 2033, driven by demand for safe, animal-free protein alternatives in the biopharmaceutical industry.
Future Plans
Evonik plans to expand its recombinant protein portfolio, contributing to the growth of its Precision Biosolutions. This collaboration supports the development of innovative biopharmaceuticals and strengthens Evonik's position in the market.
